Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,551 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma.
Khanna P, Soh HJ, Chen CH, Saxena R, Amin S, Naughton M, Joslin PN, Moore A, Bakouny Z, O'Callaghan C, Catalano P, Signoretti S, McKay R, Choueiri TK, Bhasin M, Walther T, Bhatt RS. Khanna P, et al. Among authors: saxena r. Sci Transl Med. 2021 Jan 20;13(577):eabc0170. doi: 10.1126/scitranslmed.abc0170. Sci Transl Med. 2021. PMID: 33472951
Genome-wide association analysis of composite sleep health scores in 413,904 individuals.
Goodman MO, Faquih T, Paz V, Nagarajan P, Lane JM, Spitzer B, Maher M, Chung J, Cade BE, Purcell SM, Zhu X, Noordam R, Phillips AJK, Kyle SD, Spiegelhalder K, Weedon MN, Lawlor DA, Rotter JI, Taylor KD, Isasi CR, Sofer T, Dashti HS, Rutter MK, Redline S, Saxena R, Wang H. Goodman MO, et al. Among authors: saxena r. Commun Biol. 2025 Jan 24;8(1):115. doi: 10.1038/s42003-025-07514-0. Commun Biol. 2025. PMID: 39856408 Free article.
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798579 Clinical Trial.
Outcomes of catheter ablation in cardiac sarcoidosis patients with ventricular tachycardia: a propensity score-matched retrospective analysis.
Al Taii H, Saxena R, Morcos R, Al-Shammari AS, Farhat K, Al Sakini AS, Al-Wssawi A, Gaalema D, Naraynan A, Sabayon D, Albani A, Jneid H. Al Taii H, et al. Among authors: saxena r. J Interv Card Electrophysiol. 2025 Jan 9. doi: 10.1007/s10840-025-01986-0. Online ahead of print. J Interv Card Electrophysiol. 2025. PMID: 39786700
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.
Clarke JM, Simon GR, Mamdani H, Gu L, Herndon JE 2nd, Stinchcombe TE, Ready N, Crawford J, Sonpavde G, Balevic S, Nixon AB, Campa M, Gottlin EB, Li H, Saxena R, He YW, Antonia S, Patz EF Jr. Clarke JM, et al. Among authors: saxena r. Nat Commun. 2025 Jan 2;16(1):93. doi: 10.1038/s41467-024-55092-2. Nat Commun. 2025. PMID: 39747856 Free PMC article. Clinical Trial.
2,551 results